02548nam a2200481 i 4500 000711120 StDuBDS 20240202172917.0 20160518115752.0 m||||||||d|||||||| cr ||||||||||| 160408s2016 enka fo 000|0|eng|d NEZPRACOVANÝ IMPORT 9781473974401 (ebook) : No price (OCoLC)1017715158 StDuBDS eng StDuBDS rda pn HD49 658.4056 23 Elias, Jaan, author. Merck & Co : after Vioxx, the government and the pharmaceutical industry reconsider the balance between innovation, safety, and cost / Jaan Elias, Spencer Hutchins & Andrea Nagy. [London] : SAGE, 2016. 1 online resource : illustrations (black and white, and colour). text rdacontent still image rdacontent computer rdamedia online resource rdacarrier SAGE knowledge. Cases Originally Published in: Elias, J., Hutchins, S., & Nagy, A. (2006). Merck & Co. After Vioxx, the Government and the Pharmaceutical Industry Reconsider the Balance between Innovation, Safety, and Cost. 06-013. New Haven, CT: Yale School of Management, Yale University. Merck & Co. had built an enviable reputation not just as a paragon of the pharmaceutical industry but as one of America's most admired businesses. The company had produced medical breakthrough after medical breakthrough, engaged in extensive philanthropy, and instituted progressive human resources policies, all the while delivering stellar financial performance. And yet, after withdrawing its blockbuster drug Vioxx in September of 2004, Merck found its reputation and its financial stability in danger. This case examines the challenges that faced Merck in the wake of the Vioxx recall. Description based on online resource; title from home page (viewed on May 3, 2016). elektronické knihy fd186907 czenas electronic books eczenas Merck & Co. Crisis management Case studies. Hutchins, Spencer, author. Nagy, Andrea, author. SAGE knowledge. Cases. SAGE knowledge https://sk.sagepub.com/cases/merck-co-vioxx-government-pharmaceutical-innovation-safety-cost Plný text SBC EB NEPOSILAT EB